OncoMatch/Breast Cancer/PGR (PR)

Breast CancerPGR (PR) Clinical Trials

Progesterone receptor (PR) expression is assessed alongside ER as part of hormone receptor testing and influences prognosis and treatment planning. PR positivity typically co-occurs with ER positivity and correlates with better endocrine therapy response. Trials enrolling HR+ patients (ER+ and/or PR+) include CDK4/6 inhibitor combinations, PI3K/AKT pathway agents, antibody-drug conjugates, and endocrine backbone strategies.